Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "RNA Interference Therapy-Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.
The "RNA Interference Therapy - Competitive Landscape 2026" report offers an in-depth analysis of over 40 companies and more than 90 drugs within the RNA Interference Therapy sector. This comprehensive document evaluates therapeutics based on product type, development stage, route of administration, and molecule type, while also highlighting inactive pipeline products worldwide.
RNA interference (RNAi) acts as a crucial mechanism for gene silencing, employing small RNA guides for sequence-specific mRNA degradation. Developed initially from C. elegans, RNAi therapeutics provide promising alternative treatment options, especially where conventional drug technologies such as small-molecule drugs and monoclonal antibodies face challenges. This makes RNAi a potential game-changer in drug development, especially in addressing mutational resistance in infectious diseases.
RNAi therapies utilize small RNA duplexes, including miRNA mimics, siRNAs, shRNAs, and dsiRNAs, each with ongoing clinical trials. Key focus areas of RNAi include managing toxicity, efficacy, and delivery, given that improper target recognition or immunogenic effects can pose risks.
While RNAi technology progresses rapidly, complexities in its mechanism still require research. Nevertheless, its transformative impact on functional genomics and potential in therapeutic interventions is clear, especially for conditions related to viral infections, including studies on SARS-CoV and SARS-CoV-2.
Latest Developments
- In February 2026, SanegeneBio announced a global licensing agreement with Genentech to advance one of its RNAi programs using their proprietary platform, granting Genentech global rights for development and commercialization.
- In September 2025, Arrowhead Pharmaceuticals inked a collaboration with Novartis for ARO-SNCA, targeting alpha-synuclein for synucleinopathies like Parkinson's Disease, leveraging Arrowhead's TRiMT platform.
- In March 2023, Alnylam Pharmaceuticals expanded its partnership with Medison Pharma to cover multiple regions beyond Israel, aiming to provide access to innovative RNAi therapies.
- Multiple collaborations with various corporate entities reflect the active and evolving landscape in RNAi therapeutic development, focusing on diseases like chronic hepatitis B, severe CNS conditions, and complement-mediated diseases.
RNA Interference Therapy: Company and Product Profiles
- Alnylam Pharmaceuticals: A pioneer in RNAi therapeutics, offering innovative treatments like Patisiran and Inclisiran for conditions like amyloidosis and hypercholesterolemia.
- Lumasiran: Marketed as OXLUMO, this RNAi therapeutic targets hydroxyacid oxidase 1 (HAO1) for treating primary hyperoxaluria type 1 (PH1), with regulatory nods from FDA and EMA.
- Cemdisiran: An investigational RNAi therapeutic targeting the C5 complement pathway, undergoing Phase III trials for conditions such as PNH and Myasthenia Gravis.
- Key Commercial Developments: The report details collaborations, acquisitions, and licensing deals pivotal to RNAi therapeutic landscape evolution, offering a comparative arena assessment by therapy, stage, and technology.
Companies Featured
- Silence Therapeutics
- Janssen Research & Development
- Eli Lilly and Company
- Arrowhead Pharmaceuticals
- Sylentis
- Sirnaomics
- Dicerna Pharmaceuticals
- Suzhou Ribo Life Science
- Alnylam Pharmaceuticals
- Suzhou Ribo Life Science
- Vir Biotechnology
- Arbutus Biopharma
- Silenseed
- OliX Pharmaceuticals
- Bio-Path Holdings
Key Topics Covered:
Introduction
Executive Summary
RNA Interference Therapy: Overview
- Causes
- Types
- Application
- Limitation
- Approved Therapies
RNA Interference Therapy - Analytical Perspective: In-depth Commercial Assessment
- RNA Interference Therapy Collaboration Analysis by Companies
Competitive Landscape
- Comparative Assessment of Companies (by therapy, development stage, and technology)
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
RNA Interference Therapy: Company and Product Profiles (Marketed Therapies)
Alnylam Pharmaceuticals
- Company Overview
Lumasiran
- Product Description
- Research and Development Activities
- Product Developmental Activities
RNA Interference Therapy: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
- Comparative Analysis
Alnylam Pharmaceuticals/Regeneron Pharmaceuticals
- Company Overview
Cemdisiran
- Product Description
- Research and Development Activities
- Product Developmental Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Alnylam Pharmaceuticals
- Company Overview
ALN-6400
- Product Description
- Research and Development Activities
- Product Developmental Activities
Early Stage Products (Phase I)
- Comparative Analysis
ADARx Pharmaceuticals
- Company Overview
ADX-850
- Product Description
- Research and Development Activities
- Product Developmental Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Avidity Biosciences
- Company Overview
AOC 1086
- Product Description
- Research and Development Activities
- Product Developmental Activities
Inactive Products
- Comparative Analysis
RNA Interference Therapy- Unmet needs
RNA Interference Therapy - Market drivers and barriers
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/vtaxrm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
